Dr Reddys Laboratories Upgraded to Hold on Technical and Valuation Improvements

Technical Trends Shift to Neutral Territory

The primary catalyst for the rating upgrade stems from a marked change in the technical grade, which has moved from mildly bearish to a sideways trend. This shift indicates a stabilisation in price momentum after a period of weakness. Weekly technical indicators such as the MACD and KST have turned bullish, signalling potential upward momentum in the near term. Meanwhile, monthly MACD and KST remain mildly bearish, suggesting some caution is warranted over a longer horizon.

Bollinger Bands on both weekly and monthly charts have turned mildly bullish, reflecting reduced volatility and a possible consolidation phase. However, daily moving averages still show a mildly bearish stance, highlighting short-term pressure on the stock price. The Dow Theory readings on weekly and monthly timeframes are mildly bullish, reinforcing the notion of a tentative recovery in market sentiment.

Overall, the technical picture is one of cautious optimism, with key momentum indicators improving but not yet signalling a definitive uptrend. This technical stabilisation has been a significant factor in the upgrade to a Hold rating.

Valuation Remains Attractive Amidst Market Volatility

Dr Reddys Laboratories currently trades at ₹1,275.05, down 1.39% on the day, with a 52-week high of ₹1,377.95 and a low of ₹1,025.90. The stock’s Price to Book Value ratio stands at a reasonable 2.9, which is attractive relative to its sector peers and historical averages. This valuation level suggests the stock is fairly priced, neither excessively expensive nor deeply undervalued.

Despite a PEG ratio of 5.2, which indicates a premium relative to earnings growth, the company’s long-term growth prospects support this valuation. Net sales have grown at an annualised rate of 13.12%, while operating profit has expanded at 18.90% per annum, underscoring robust underlying business momentum. The stock’s one-year return of 15.09% outpaces the Sensex’s 2.27% gain over the same period, further justifying the Hold rating from a valuation perspective.

Financial Trend: Mixed Quarterly Results but Strong Long-Term Fundamentals

While the company reported negative financial performance in Q3 FY25-26, with Profit Before Tax (excluding other income) falling 18.3% to ₹1,274.40 crores and Profit After Tax declining 16.2% to ₹1,209.90 crores compared to the previous four-quarter average, the broader financial trend remains positive. Return on Capital Employed (ROCE) for the half-year is at a low 18.75%, indicating some pressure on capital efficiency in the short term.

However, Dr Reddys Laboratories maintains a low average Debt to Equity ratio of 0.01 times, reflecting a conservative capital structure and limited financial risk. The company’s average Return on Equity (ROE) of 15.78% demonstrates strong profitability relative to shareholder funds, supporting confidence in its long-term earnings power. These fundamentals underpin the Hold rating despite recent quarterly setbacks.

Quality Assessment: Large-Cap Stability with Institutional Backing

Dr Reddys Laboratories is classified as a large-cap company within the Pharmaceuticals & Biotechnology sector, with a Mojo Score of 54.0 and a Mojo Grade upgraded from Sell to Hold as of 16 March 2026. This reflects a moderate quality rating, balancing the company’s established market position against recent performance challenges.

Institutional investors hold a significant 63.64% stake in the company, signalling strong confidence from sophisticated market participants who typically conduct rigorous fundamental analysis. This institutional backing provides a stabilising influence on the stock and supports the revised rating.

Stock Performance Relative to Sensex

Over various timeframes, Dr Reddys Laboratories has delivered mixed but generally positive returns relative to the Sensex benchmark. The stock outperformed the Sensex over the past week (-0.88% vs -2.66%), one month (+0.45% vs -9.34%), year-to-date (+0.31% vs -11.40%), one year (+15.09% vs +2.27%), and three years (+45.45% vs +31.00%). However, over five and ten years, the Sensex has outpaced the stock with returns of 49.91% and 205.90% respectively, compared to 43.30% and 102.04% for Dr Reddys.

This relative performance highlights the company’s resilience in recent periods, though it has lagged broader market gains over the longer term.

Outlook and Investment Implications

The upgrade to a Hold rating for Dr Reddys Laboratories Ltd reflects a balanced view of the company’s current position. The technical indicators suggest a stabilising price trend, while valuation metrics indicate the stock is fairly priced relative to its growth prospects and sector peers. Despite recent quarterly earnings declines, the company’s strong long-term fundamentals, low leverage, and high institutional ownership provide a solid foundation for future performance.

Investors should monitor upcoming quarterly results closely, as sustained earnings recovery will be critical to justify any further upgrades. Meanwhile, the sideways technical trend advises caution, suggesting that the stock may consolidate before embarking on a more definitive directional move.

Given these factors, the Hold rating is appropriate for investors seeking exposure to a large-cap pharmaceutical company with stable fundamentals but some near-term uncertainties.

Summary of Key Metrics

• Current Price: ₹1,275.05
• 52-Week Range: ₹1,025.90 – ₹1,377.95
• Price to Book Value: 2.9
• PEG Ratio: 5.2
• ROE (Average): 15.78%
• Debt to Equity (Average): 0.01 times
• Institutional Holdings: 63.64%
• Q3 FY25-26 PBT (excl. other income): ₹1,274.40 crores (-18.3%)
• Q3 FY25-26 PAT: ₹1,209.90 crores (-16.2%)
• Mojo Score: 54.0 (Hold, upgraded from Sell)

Conclusion

Dr Reddys Laboratories Ltd’s recent upgrade to Hold by MarketsMOJO reflects a comprehensive reassessment of its technical, valuation, financial, and quality parameters. While short-term earnings pressures remain, the company’s strong balance sheet, attractive valuation relative to peers, and improving technical signals support a more neutral stance. Investors should weigh these factors carefully and consider the stock’s role within a diversified portfolio amid ongoing sector and market dynamics.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today